Non-destructive methods of characterization of risperidone solid lipid nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 1, 2010, Pages 127-137

  Rahman, Ziyaur ^a   Zidan, Ahmed S ^a   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Compritol 888 ATO; NIR; NIR CI; Risperidone; SLN

Indexed keywords

DODECYL SULFATE SODIUM; GLYCEROL BEHENATE; RISPERIDONE; SOLID LIPID NANOPARTICLE;

ARTICLE; CHEMOMETRIC ANALYSIS; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; EVAPORATION; FOURIER TRANSFORM MASS SPECTROMETRY; NEAR INFRARED SPECTROSCOPY; RESPONSE SURFACE METHOD; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

EID: 77955659891     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.05.003     Document Type: Article

References (37)

1. Chauhan N.B. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. Antisense Nucl. Acid Drug Dev. 2002, 12:353-357.
2. Grondin R., Zhang Z., Ai Y., Gash D.M., Gerhardt G.A. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res. 2003, 61:101-123.
3. Guerin C., Olivi A., Weingart J.D., Lawson H.C., Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs 2004, 22:27-37.
4. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci. 2003, 6:252-273.
5. Pardridge W.M. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv. Exp. Med. Biol. 2002, 513:397-430.
6. Bagger M.A., Bechgaard E. The potential of nasal application for delivery to the central brain a microdialysis study of fluorescenin in rats. Eur. J. Pharm. Sci. 2004, 21:235-242.
7. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92:1343-1355.
8. Saito R., Bringas J.R., McKnight T.R., Wendland M.F., Mamot C., Drummond D.C., Kirpotin D.B., Park J.W., Berger M.S., Bankiewicz K.S. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004, 64:2572-2579.
9. Wong H.L., Chattopadhyay N., Wu X.Y., Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev. 2009.
10. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 2008, 127:97-109.
11. Freitas C., Müller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions. Int. J. Pharm. 1998, 168:221-229.
12. Muller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
13. Gohla S.H., Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN™). Pharmazie 2001, 56:61-63.
14. International conference of harmonization, Pharm. Dev., Q8 (R2), 2009.
15. Box G., Behnken D. Some new three level designs for the study of quantitative variables. Technometrics 1960, 2:455-475.
16. Chopra S., Patil G.V., Motwani S.K. Release modulating hydrophilic matrix systems of losartan potassium: optimisation of formulation using statistical experimental design. Eur. J. Pharm. Biopharm. 2007, 66:73-82.
17. Davis J.M. The choice of drugs for schizophrenia. N. Engl. J. Med. 2006, 354:1846-1848.
18. Yan J. Risperidone approved to treat schizophrenia in children. Psychiatric News 2007, 42:1.
19. Rahman Z., Kohli K., Khar R.K., Ali M., Charoo N.A., Shamsher A.A.A. Characterization of 5-Fluorouracil microspheres for colonic delivery. AAPS Pharm. Sci. Technol. 2006, 7:E1-E9.
20. Suthar A.P., Dubey S.A., Patel S.R., Shah A.M. Determination of Risperidone and forced degradation behavior by HPLC in tablet dosage form. Int. J. Pharm. Technol. Res. 2009, 1:568-574.
21. International conference of harmonization-validation of analytical procedures, Q2(R1), 2005.
22. Singh S., Muthu S.M. Preparation and characterization of nanoparticles containing an atyptical antipsychotic agent. Nanomedicine 2007, 2:233-240.
23. Rahman Z., Zidan A.S., Habib M.J., Khan M.A. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int. J. Pharm. 2009.
24. Yang Y.Y., Chung T.S., Bai X.L., Chan W.K. Effect of preparation condition on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem. Eng. Sci. 2000, 55:2223-2236.
25. Yang Q., Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev. Ind. Pharm. 2000, 26:61-70.
26. Couvreur P., Blanco-Prieto M.J., Puisieux F., Roques B., Fattal E. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv. Drug Deliv. Rev. 1997, 28:85-96.
27. Yang Y.Y., Chung T.S., Ng N.P. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomate 2001, 22:231-241.
28. Jalil R., Nixon J.R. Microencapsulation using poly(l-lactic acid) I: microcapsule properties affected by the preparation technique. J. Microencapsul. 1989, 6:473-484.
29. Rahman Z., Zidan A.S., Habib M.J., Khan M.A. Formulation and evaluation of a protein loaded solid dispersions by non-destructive methods. AAPS J. 2010.
30. Zidan A.S., Rahman Z., Habib M.J., Khan M.A. Spectral and spatial characterization of protein loaded PLGA nanoparticles. J. Pharm. Sci. 2010, 99:1180-1192.
31. Heigl N., Petter C.H., Lieb M., Bonn G.K., Huck C.W. Near-infrared reflection spectroscopy and partial least squares regression for determining the total carbon coverage of silica packings for liquid chromatography. Vib. Spectrosc. 2009, 49:155-161.
32. Smith R.C., Baker K.S. Optical properties of clearest natural waters (200-800 nm). Appl. Opt. 1981, 20:177-184.
33. Geladi P., MacDougall D., Martens H. Linearization and scatter-correction for near-infrared reflectance spectra of meat. Appl. Spectrosc. 1985, 39:491-500.
34. Barnes R.J., Dhanoa M.S., Lister S.J. Standard normal variate transformation and de-trending of near-infrared diffuse reflectance spectra. Appl. Spectrosc. 1989, 43:772-777.
35. Tahboub Y.R., Pardue H.L. Evaluation of multiwavelength first- and second-derivative spectra for the quantitation of mixtures of polynuclear aromatic hydrocarbons. Anal. Chem. 1985, 57:38-41.
36. Baratieri S.C., Barbosa J.M., Freitas M.P., Martins J.A. Multivariate analysis of nystatin and metronidazole in a semi-solid matrix by means of diffuse reflectance NIR spectroscopy and PLS regression. J. Pharm. Biomed. Anal. 2006, 40:51-55.
37. Suda M., Takayama K., Otsuk M. An accurate quantitative analysis of polymorphic content by chemometric X-ray powder diffraction. Anal. Sci. 2008, 24:451-457.